000058377 001__ 58377
000058377 005__ 20170504093356.0
000058377 0247_ $$2doi$$a10.2165/11593880-000000000-00000
000058377 0248_ $$2sideral$$a74018
000058377 037__ $$aART-2011-74018
000058377 041__ $$aeng
000058377 100__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000058377 245__ $$aShort-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - Gastrointestinal adverse effects: A meta-analysis of randomized clinical trials
000058377 260__ $$c2011
000058377 5060_ $$aAccess copy available to the general public$$fUnrestricted
000058377 5203_ $$aBackground and Aim: Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited. The aim of this study was to provide data on the safety of this treatment pattern, which is of interest to clinicians, regulators, and the public.
Methods: A meta-analysis of individual patient data from 67 studies sponsored by Bayer HealthCare was completed. The primary endpoints were patient-reported gastrointestinal (GI) adverse events (AEs); the secondary endpoints were the incidence of patient-reported non-GI AEs. Event incidence and odds ratios (ORs) based on Cochran-Mantel-Haenszel estimates are reported. In total, 6181 patients were treated with ASA, 3515 with placebo, 1145 with acetaminophen (paracetamol), and 754 with ibuprofen. Exposure to ASA was short term (82.5% of patients had a single dose).
Results: GI AEs were more frequent with ASA (9.9%) than with placebo (9.0%) [OR 1.3; 95% CI 1.1, 1.5]. Dyspeptic symptoms were infrequent (4.6% in placebo subjects). The ORs for ASA were 1.3 (95% CI 1.1, 1.6) versus placebo; 1.55 (95% CI 0.7, 3.3) versus ibuprofen; and 1.04 (95% CI 0.8, 1.4) versus acetaminophen. There were very few serious GI AEs (one ASA case; three placebo cases). No differences were found for non-GI AEs and no cases of cerebral hemorrhage were reported.
Conclusion: Short-term, mostly single-dose exposure to ASA for the treatment of pain, fever, or colds was associated with a small but significant increase in the risk of dyspepsia relative to placebo.No serious GI complications were reported.
000058377 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000058377 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000058377 700__ $$aMcCarthy, D.
000058377 700__ $$aVoelker, M.
000058377 700__ $$aBrueckner, A.
000058377 700__ $$aSenn, S.
000058377 700__ $$aBaron, J.A.
000058377 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDepartamento de Medicina, Psiquiatría y Dermatología$$cMedicina
000058377 773__ $$g11, 3 (2011), 277-288$$pDRUGS IN R&D$$tDRUGS IN R&D$$x1174-5886
000058377 8564_ $$s159059$$uhttps://zaguan.unizar.es/record/58377/files/texto_completo.pdf$$yVersión publicada
000058377 8564_ $$s62678$$uhttps://zaguan.unizar.es/record/58377/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000058377 909CO $$ooai:zaguan.unizar.es:58377$$particulos$$pdriver
000058377 951__ $$a2017-05-04-09:33:10
000058377 980__ $$aARTICLE